Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial
- 1 January 1996
- journal article
- clinical trial
- Published by Walter de Gruyter GmbH in jpme
- Vol. 24 (6) , 609-620
- https://doi.org/10.1515/jpme.1996.24.6.609
Abstract
The objective of this prospective, multicentre trial, carried out at 18 third level hospitals in Italy, was to evaluate efficacy of modified porcine surfactant (Curosurf), administered at birth to prevent the development of respiratory distress syndrome (RDS) in premature infants. 287 babies with a gestational age of 24-30 weeks were randomized to prophylactic treatment with Curosurf (80 mg/ml; dose 20 mg/kg) or to a control group receiving no surfactant treatment in the delivery-room. Babies in both groups were eligible for rescue treatment with surfactant (200 mg/kg) if they developed clinical symptoms of RDS and required mechanical ventilation. The main end-point was to obtain, in the prophylaxis group, a 30% reduction in the incidence of grade 3-4 RDS. Median gestational age was 28 weeks in both groups and mean birth weight 1010 and 1002 g, respectively for prophylaxis and control babies. There was a 32% reduction in the incidence of grade 3-4 RDS in the prophylaxis group (p < 0.05). This was associated with a significant reduction in mean maximum fraction of inspired oxygen (0.57 vs 0.66%; p < 0.01), a decreased incidence of pulmonary interstitial emphysema (7 vs 14%; p < 0.05) and a lowered mortality (21 vs 35%; p < 0.01). Combined unfavourable outcome (mortality + bronchopulmonary dysplasia and/or grade 3-4 intraventricular hemorrhage and/or grade 2-4 retinopathy of prematurity) was significantly lower in the prophylaxis than in the second group (41 vs 58%; p < 0.01). The favourable effects of prophylactic treatment were equally recorded in all the age groups, including the babies with the lowest gestational age (24-25 weeks). Multiple and logistic regression analysis confirmed that high gestational age and surfactant prophylaxis were, independently, associated with a lower degree of RDS (p = 0.0001 and p = 0.0008, respectively) and a lower mortality (p = 0.0001 and p = 0.0045, respectively). We conclude that prophylaxis with modified natural surfactant effectively prevents RDS in newborn babies between 24 and 30 weeks' gestation.Keywords
This publication has 21 references indexed in Scilit:
- Correlations between radiological and cytological findings in early development of bronchopulmonary dysplasiaEuropean Journal of Pediatrics, 1993
- Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndromejpme, 1993
- Relative likelihood of bronchopulmonary dysplasia based on pulmonary mechanics measured in preterm neonates during the first week of lifeThe Journal of Pediatrics, 1992
- Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndromeEuropean Journal of Pediatrics, 1991
- Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturityThe Journal of Pediatrics, 1991
- A Comparison of Surfactant as Immediate Prophylaxis and as Rescue Therapy in Newborns of Less Than 30 Weeks' GestationNew England Journal of Medicine, 1991
- Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestationEarly Human Development, 1988
- Cardiovascular effects of patent ductus arteriosus in preterm lambs with respiratory distressThe Journal of Pediatrics, 1987
- Prophylactic Treatment of Very Premature Infants with Human SurfactantNew England Journal of Medicine, 1986
- Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gmThe Journal of Pediatrics, 1978